|
1
|
Ganesan M, Poluektova LY, Kharbanda KK and
Osna NA: Human immunodeficiency virus and hepatotropic viruses
co-morbidities as the inducers of liver injury progression. World J
Gastroenterol. 25:398–410. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gobran ST, Ancuta P and Shoukry NH: A Tale
of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.
Front Immunol. 12(726419)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chen M, Wong WW, Law MG, Kiertiburanakul
S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee
MP, et al: Hepatitis B and C Co-Infection in HIV Patients from the
TREAT Asia HIV observational database: Analysis of risk factors and
survival. PLoS One. 11(e0150512)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Akekawatchai C, Sretapunya W,
Pipatsatitpong D and Chuenchit T: Hepatitis B or C virus
coinfection in and risks for transaminitis in human
immunodeficiency virus-infected Thais on combined antiretroviral
therapy. Asian Biomedicine. 9:353–361. 2015.
|
|
5
|
Law WP, Dore GJ, Duncombe CJ,
Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P and
Cooper DA: Risk of severe hepatotoxicity associated with
antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
AIDS. 17:2191–2199. 2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sungkanuparph S, Wongprasit P, Manosuthi W
and Atamasirikul K: Compliance with hepatitis B and hepatitis C
virus infection screening among HIV-1 infected patients in a
resource-limited setting. Southeast Asian J Trop Med Public Health.
39:863–866. 2008.PubMed/NCBI
|
|
7
|
Thitipatarakorn S, Chinbunchorn T, Peelay
J, Seekaew P, Amatavete S, Sangsai M, Pankam T, Avihingsanon A,
Avery M, Phanuphak P, et al: Prevalence and the associated factors
of hepatitis B and hepatitis C viral infections among HIV-positive
individuals in same-day antiretroviral therapy initiation program
in Bangkok, Thailand. BMC Public Health. 22(144)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sun J, Althoff KN, Jing Y, Horberg MA,
Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, et
al: Trends in hepatocellular carcinoma incidence and risk among
persons with HIV in the US and Canada, 1996-2015. JAMA Netw Open.
4(e2037512)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
DallaPiazza M, Amorosa VK, Localio R,
Kostman JR and Lo Re V III: Prevalence and risk factors for
significant liver fibrosis among HIV-monoinfected patients. BMC
Infect Dis. 10(116)2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chiraunyanann T, Changsri K, Sretapunya W,
Yuenyongchaiwat K and Akekawatchai C: CXCL12 G801A polymorphism is
associated with significant liver fibrosis in HIV-infected Thais: A
cross-sectional study. Asian Pac J Allergy Immunol. 37:162–170.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Androutsakos T, Schina M, Pouliakis A,
Kontos A, Sipsas N and Hatzis G: Causative factors of liver
fibrosis in HIV-infected patients. A single center study. BMC
Gastroenterol. 20(91)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
de Torres M and Poynard T: Risk factors
for liver fibrosis progression in patients with chronic hepatitis
C. Ann Hepatol. 2:5–11. 2003.PubMed/NCBI
|
|
13
|
Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ,
Khan MM and Lau DT: Risk of hepatocellular carcinoma after
hepatitis C virus cure. World J Gastroenterol. 28:96–107.
2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nguyen Truong T, Laureillard D, Lacombe K,
Duong Thi H, Pham Thi Hanh P, Truong Thi Xuan L, Chu Thi N, Luong
Que A, Vu Hai V, Nagot N, et al: High Proportion of HIV-HCV
coinfected patients with advanced liver fibrosis requiring
hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
PLoS One. 11(e0153744)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tadesse WT, Adankie BT, Shibeshi W, Amogne
W, Aklillu E and Engidawork E: Prevalence and predictors of glucose
metabolism disorders among People Living with HIV on combination
antiretroviral therapy. PLoS One. 17(e0262604)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Waters DD and Hsue PY: Lipid abnormalities
in persons living with HIV infection. Can J Cardiol. 35:249–259.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Somkid Srisopa DP and Chaereeporn
Akekawatchai: Genotypic distribution of hepatitis C virus in human
immunodeficiency virus-infected patients in Bamrasnaradura
Infectious Diseases Institute. Journal of the Medical Technologist
Association of Thailand. 48:7215–7226. 2020.
|
|
18
|
Cloherty G, Talal A, Coller K, Steinhart
C, Hackett J Jr, Dawson G, Rockstroh J and Feld J: Role of
serologic and molecular diagnostic assays in identification and
management of hepatitis C virus infection. J Clin Microbiol.
54:265–273. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sterling RK, Lissen E, Clumeck N, Sola R,
Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT,
Thomas DL, et al: Development of a simple noninvasive index to
predict significant fibrosis in patients with HIV/HCV coinfection.
Hepatology. 43:1317–1325. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Foca E, Fabbiani M, Prosperi M, Quiros
Roldan E, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S,
Gagliardini R, Saracino A, et al: Liver fibrosis progression and
clinical outcomes are intertwined: Role of CD4+ T-cell count and
NRTI exposure from a large cohort of HIV/HCV-coinfected patients
with detectable HCV-RNA: A MASTER cohort study. Medicine
(Baltimore). 95(e4091)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wai CT, Greenson JK, Fontana RJ,
Kalbfleisch JD, Marrero JA, Conjeevaram HS and Lok AS: A simple
noninvasive index can predict both significant fibrosis and
cirrhosis in patients with chronic hepatitis C. Hepatology.
38:518–526. 2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Federation WaID, World Health Organization
(WHO): Definition and diagnosis of diabetes mellitus and
intermediate hyperglycarmia. WHO, Geneva, 2006.
|
|
23
|
American Diabetes Association.
Classification and diagnosis of diabetes: Standards of medical care
in diabetesd-2021. Diabetes Care. 44 (Suppl 1):S15–S33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults. Executive summary of
the third report of The National cholesterol education program
(NCEP) expert panel on detection, evaluation, and treatment of high
blood cholesterol in adults (Adult Treatment Panel III). JAMA.
285:2486–2497. 2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lelis DF, Calzavara JVS, Santos RD,
Sposito AC, Griep RH, Barreto SM, Molina MDCB, Schmidt MI, Duncan
BB, Bensenor I, et al: Reference values for the triglyceride to
high-density lipoprotein ratio and its association with
cardiometabolic diseases in a mixed adult population: The
ELSA-Brasil study. J Clin Lipidol. 15:699–711. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lertsakulbunlue S, Mungthin M, Rangsin R,
Kantiwong A and Sakboonyarat B: Trends in baseline
triglyceride-glucose index and association with predicted 10-year
cardiovascular disease risk among type 2 diabetes patients in
Thailand. Sci Rep. 13(12960)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zeremski M, Dimova RB, Pillardy J, de Jong
YP, Jacobson IM and Talal AH: Fibrosis progression in patients with
chronic hepatitis C virus infection. J Infect Dis. 214:1164–1170.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Medrano LM, Garcia-Broncano P, Berenguer
J, González-García J, Jiménez-Sousa MÁ, Guardiola JM, Crespo M,
Quereda C, Sanz J, Canorea I, et al: Elevated liver stiffness is
linked to increased biomarkers of inflammation and immune
activation in HIV/hepatitis C virus-coinfected patients. AIDS.
32:1095–1105. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Portocarrero Nunez JA, Gonzalez-Garcia J,
Berenguer J, Gallego MJV, Loyarte JAI, Metola L, Bernal E, Navarro
G, Del Amo J and Jarrín I: and the Cohort of the Spanish HIV
Research Network (CoRIS). Impact of co-infection by hepatitis C
virus on immunological and virological response to antiretroviral
therapy in HIV-positive patients. Medicine (Baltimore).
97(e12238)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Corey KE, Kane E, Munroe C, Barlow LL,
Zheng H and Chung RT: Hepatitis C virus infection and its clearance
alter circulating lipids: Implications for long-term follow-up.
Hepatology. 50:1030–1037. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Miyazaki T, Honda A, Ikegami T, Saitoh Y,
Hirayama T, Hara T, Doy M and Matsuzaki Y: Hepatitis C virus
infection causes hypolipidemia regardless of hepatic damage or
nutritional state: An epidemiological survey of a large Japanese
cohort. Hepatol Res. 41:530–541. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Boemeke L, Bassani L, Marroni CA and
Gottschall CB: Lipid profile in cirrhotic patients and its relation
to clinical outcome. Arq Bras Cir Dig. 28:132–135. 2015.PubMed/NCBI View Article : Google Scholar : (In English,
Portuguese).
|
|
33
|
Del Campo JA and Romero-Gomez M:
Modulation of host lipid metabolism by hepatitis C virus: Role of
new therapies. World J Gastroenterol. 21:10776–10782.
2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liver TAftSot: Thailand Practice Guideline
for Management of Chronic Hepatitis B and C 2015. https://thasl.org/en/thasl-guideline-2/.
|
